Alnylam Pharmaceuticals Inc (ALNY)vsErasca Inc (ERAS)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
ERAS
Erasca Inc
$14.67
+2.44%
HEALTHCARE · Cap: $4.54B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
ERAS
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for ERAS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Trading at 12.9x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : ERAS
ERAS has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : ERAS
The primary concerns for ERAS are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while ERAS is a value play — different risk/reward profiles.
ERAS carries more volatility with a beta of 1.17 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 25/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Erasca Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Erasca Inc. is a forward-thinking biopharmaceutical company focused on creating targeted therapies for genetically defined cancers to meet significant unmet medical needs in oncology. Utilizing a proprietary drug discovery platform that merges advanced genomics with precision medicine, Erasca concentrates on developing treatments that specifically target key mutations driving cancer progression. With a diverse pipeline of clinical-stage candidates designed to inhibit critical tumor growth pathways, the company aims to enhance the standards of cancer care. Erasca’s commitment to improving patient outcomes is further strengthened by its strategic collaborations and partnerships within the cancer research landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?